Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval. In October, Novartis acquired US and Canadian commercialization rights to the pill from Vanda, which retains ex-US marketing rights. A long-acting injectable (depot) formulation is being developed.
Mobile clinical-software outfit Epocrates hired Geoffrey Rutledge, MD, PhD, as chief medical officer and EVP, product development. Rutledge, who has held senior-management roles with WebMD and First Consulting Group, will oversee Epocrates’ medical-information team and lead the development of new products.
CRM firm Cegedim Dendrite acquired healthcare data provider SK&A Information Services for an undisclosed sum. SK&A maintains a telephone-verifiable database of contact records used by pharma clients for commercial planning and operations. The firm will be branded as SK&A, A Cegedim Company.
From the February 01, 2010 Issue of MM+M - Medical Marketing and Media
